<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538329</url>
  </required_header>
  <id_info>
    <org_study_id>11 253 01</org_study_id>
    <nct_id>NCT01538329</nct_id>
  </id_info>
  <brief_title>Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease</brief_title>
  <acronym>PREMANDYSK</acronym>
  <official_title>Impact of Amantadine on L-DOPA-induced Dyskinesia in Early Parkinson's Disease: a Placebo-controlled Randomized Study (the PREMANDYSK Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the&#xD;
      early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This&#xD;
      treatment is usually maintained for no more than the first few months of management, before&#xD;
      resorting to drugs deemed more effective as dopamine agonists and lévo-DOPA (L-DOPA). A more&#xD;
      modern use of the drug is at a more advanced stage of PD when dyskinesia are already&#xD;
      established and become disabling for the patients. There is no data between these two&#xD;
      extremes of life stages of Parkinsonism. However, the mechanisms of action of amantadine and&#xD;
      the pathophysiology of the motor complications induced by L-DOPA, in particular dyskinesia&#xD;
      suggest that the early and prolonged use of amantadine in the early years of management,&#xD;
      before L-DOPA-induced dyskinesia have already emerged, should have a positive impact on&#xD;
      long-term occurrence and fate of these symptoms, possibly through a glutamatergic mechanism&#xD;
      of brain plasticity-of the &quot;disease modification&quot; type.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally amantadine is used at the beginning of Parkinson Disease (PD) treatment in the&#xD;
      early stages of the disease, as a modest antiparkinsonian symptomatic treatment. This&#xD;
      treatment is usually maintained for no more than the first few months of management, before&#xD;
      resorting to drugs deemed more effective as dopamine agonists and lévo-DOPA (L-DOPA). A more&#xD;
      modern use of the drug is at a more advanced stage of PD when dyskinesia are already&#xD;
      established and become disabling for the patients. There is no data between these two&#xD;
      extremes of life stages of Parkinsonism. However, the mechanisms of action of amantadine and&#xD;
      the pathophysiology of the motor complications induced by L-DOPA, in particular dyskinesia&#xD;
      suggest that the early and prolonged use of amantadine in the early years of management,&#xD;
      before L-DOPA-induced dyskinesia have already emerged, should have a positive impact on&#xD;
      long-term occurrence and fate of these symptoms, possibly through a glutamatergic mechanism&#xD;
      of brain plasticity-of the &quot;disease modification&quot; type.&#xD;
&#xD;
      The primary purpose of this study is to demonstrate that early introduction of treatment with&#xD;
      amantadine (200 mg / d) in the early years of therapeutic care, that is to say during the&#xD;
      &quot;honeymoon&quot; of levodopa (early phase of disease &lt;3 years of diagnosis &lt;1 year of L-dopa and&#xD;
      lack of complications of levodopa therapy) decreases the rate of subjects with abnormal&#xD;
      involuntary dyskinetic movements after 18 months of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2012</start_date>
  <completion_date type="Actual">February 26, 2019</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>after 18 months of Phase 1 of the study</measure>
    <time_frame>after 18 months of follow-up</time_frame>
    <description>Rate of patient with abnormal involuntary dyskinetic movements (as specifically defined in the protocol) after 18 months of Phase 1 of the study (amantadine versus placebo).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out)</measure>
    <time_frame>22 months after inclusion</time_frame>
    <description>Rate of patients with abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>motor fluctuations after 18 months of Phase 1 of the study</measure>
    <time_frame>18 months after inclusion</time_frame>
    <description>Rate of patients with non-motor fluctuations after 18 months of Phase 1 (defined by the specific scale developed by the Marseille team involved in the project)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to onset of dyskinesias</measure>
    <time_frame>each visits</time_frame>
    <description>Time to onset of dyskinesias defined as the study visit at which the investigator answers &quot;yes&quot; for the first time the question &quot;do you think this patient has dyskinesia as defined in Protocol &quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with amantadine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with amantadine placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>200mg / day once daily in the morning and at noon - oral administration -</description>
    <arm_group_label>Amantadine</arm_group_label>
    <other_name>active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>200mg / day once daily in the morning and at noon - oral administration -</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo of amantadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 35 years,&#xD;
&#xD;
          -  Patients having signed an informed consent before any specific study procedures,&#xD;
&#xD;
          -  Patients having a health Insurance Coverage (according to local regulatory&#xD;
             requirements),&#xD;
&#xD;
          -  Patients suffering from idiopathic Parkinson's disease meeting the definition criteria&#xD;
             of the UKPD Brain Bank (Gibb and Lees, 1988),&#xD;
&#xD;
          -  Parkinson's disease diagnosed for &lt;3 years,&#xD;
&#xD;
          -  Patients receiving treatment with L-DOPA from &lt;1year,&#xD;
&#xD;
          -  Lack of complications of levodopa therapy&#xD;
&#xD;
          -  Patients receiving a stable antiparkinsonian treatment that may involve, in addition&#xD;
             to L-DOPA, a dopamine agonist, a monoamine oxidase-B (MAO-B) or a catecholamine&#xD;
             O-methyl transferase (COMT) inhibitor, an anti-cholinergic for at least 2 months&#xD;
             before enrollment and in whom we presume it will be possible to maintain this&#xD;
             treatment unchanged during the study period (except the dose of L-dopa which can be&#xD;
             adjusted during the study after the third month of Phase 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atypical parkinsonian syndromes,&#xD;
&#xD;
          -  Drug-induced Parkinsonism,&#xD;
&#xD;
          -  Juvenile Parkinson,&#xD;
&#xD;
          -  Patients with complications of levodopa therapy&#xD;
&#xD;
          -  Inability to keep the current stable antiparkinsonian treatment during the study&#xD;
             period, apart from L-DOPA,&#xD;
&#xD;
          -  Pretreatment with amantadine,&#xD;
&#xD;
          -  amantadine counter-indication&#xD;
&#xD;
          -  Neuroleptic treatment,&#xD;
&#xD;
          -  Patients with dementia, Mini Mental Status (MMS) &lt;26,&#xD;
&#xD;
          -  Patient with behavioral disorder, ECMP item ≥ 3&#xD;
&#xD;
          -  Female subjects of childbearing potential without effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Rascol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHG Aix en Provence</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Jean Rougier</name>
      <address>
        <city>Cahors</city>
        <zip>46005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHu de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Narbonne</name>
      <address>
        <city>Narbonne</city>
        <zip>11108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital pitié Salpétriére</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyskinesia</keyword>
  <keyword>L-DOPA</keyword>
  <keyword>Early introduced treatment</keyword>
  <keyword>Amantadine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

